Laura W. Goff

5.8k total citations
77 papers, 2.0k citations indexed

About

Laura W. Goff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Laura W. Goff has authored 77 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 21 papers in Surgery. Recurrent topics in Laura W. Goff's work include Pancreatic and Hepatic Oncology Research (27 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers) and Colorectal Cancer Treatments and Studies (13 papers). Laura W. Goff is often cited by papers focused on Pancreatic and Hepatic Oncology Research (27 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers) and Colorectal Cancer Treatments and Studies (13 papers). Laura W. Goff collaborates with scholars based in United States, Italy and South Korea. Laura W. Goff's co-authors include Jordan Berlin, Wael El‐Rifai, Shahana Majid, Altaf A. Dar, Neeta K. Venepalli, Dana B. Cardin, Tanios Bekaii‐Saab, Ahmed Katsha, Bert H. O’Neil and John Kauh and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Laura W. Goff

75 papers receiving 2.0k citations

Peers

Countries citing papers authored by Laura W. Goff

Since Specialization

Citations

This map shows the geographic impact of Laura W. Goff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura W. Goff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura W. Goff more than expected).

Fields of papers citing papers by Laura W. Goff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura W. Goff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura W. Goff. The network helps show where Laura W. Goff may publish in the future.

Co-authorship network of co-authors of Laura W. Goff

This figure shows the co-authorship network connecting the top 25 collaborators of Laura W. Goff. A scholar is included among the top collaborators of Laura W. Goff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura W. Goff. Laura W. Goff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer 2025 ·Clinical Cancer Research ·Kristen K. Ciombor, (unknown), Jennifer G. Whisenant, Gregory D. Ayers, Quanhu Sheng, Todd E. Peterson, Gary T. Smith, Kangyu Lin, Saikat Chowdhury, Preeti Kanikarla Marie, Alexey V. Sorokin, Allison S. Cohen, Laura W. Goff, Dana B. Cardin, John Paul Shen, Scott Kopetz, Cathy Eng, Yu Shyr, Jordan Berlin, (unknown)	6
2	Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma 2024 ·Current Treatment Options in Oncology ·(unknown), Rajiv Agarwal, Laura W. Goff, Natalie A. Lockney, Chandrasekhar Padmanabhan, Thatcher Heumann	7
3	P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer 2023 ·Annals of Oncology ·Kristen K. Ciombor, Jennifer G. Whisenant, Gregory D. Ayers, Cathy Eng, Laura W. Goff, Dana B. Cardin, Theresa Hickman, Gary T. Smith, Todd E. Peterson, Sejong Bae, Satya Das, H. Charles Manning, Jordan Berlin	1
4	Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies 2023 ·Cancers ·Justin H. Lo, Rajiv Agarwal, Laura W. Goff, Thatcher Heumann	25
5	Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors 2023 ·British Journal of Cancer ·Jason J. Luke, Marwan Fakih, Charles Schneider, E. Gabriela Chiorean, Johanna C. Bendell, Rebecca Kristeleit, Razelle Kurzrock, Sarah P. Blagden, Irene Braña, Laura W. Goff, Kevin O’Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing	19
6	Targeted therapies in advanced biliary tract cancers—a narrative review 2023 ·Chinese Clinical Oncology ·(unknown), Thatcher Heumann, Laura W. Goff, Rajiv Agarwal	7
7	Catching Those Who Fall Through the Cracks: Integrating a Follow-Up Process for Emergency Department Patients with Incidental Radiologic Findings 2022 ·Annals of Emergency Medicine ·Tyler W. Barrett, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sam S. Chang, Laura W. Goff, Stephan Russ, Ian D. Jones	13
8	First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-¹¹C]-Glutamine in Patients with Metastatic Colorectal Cancer 2021 ·Journal of Nuclear Medicine ·Allison S. Cohen, (unknown), Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, (unknown), Kristen K. Ciombor, Dana B. Cardin, Cathy Eng, Laura W. Goff, Satya Das, Robert J. Coffey, Jordan Berlin, H. Charles Manning	20
9	A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). 2021 ·Journal of Clinical Oncology ·Aiwu Ruth He, (unknown), (unknown), Kabir Mody, Kevin Kim, Stacey Stein, Lipika Goyal, Thomas A. Abrams, Daniel B. Brown, Laura W. Goff, Richard D. Kim, Nainesh Parikh, Tyler Sandow, Daniel Johnson, Renuka Iyer, (unknown), Smitha Krishnamurthi, Charles E. Martin, Yixing Jiang, (unknown)	4
10	Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) 2020 ·European Journal of Cancer ·Yung‐Jue Bang, Talia Golan, Laëtitia Dahan, Siqing Fu, Víctor Moreno, Keunchil Park, Ravit Geva, Filippo de Braud, Zev A. Wainberg, Martin Reck, Laura W. Goff, Naomi Laing, Gu Mi, Joana Oliveira, (unknown), Chia‐Chi Lin	103
11	Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial 2019 ·Annals of Surgical Oncology ·Alice C. Wei, Fang‐Shu Ou, Qian Shi, Xiomara W. Carrero, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Robert A. Wolff, Hedy L. Kindler, Douglas B. Evans, Vikram Deshpande, Joseph Misdraji, Eric P. Tamm, Dushyant V. Sahani, Malcolm J. Moore, Elliot Newman, Nipun B. Merchant, Jordan Berlin, Laura W. Goff, Peter W. T. Pisters, Mitchell C. Posner	19
12	Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer 2018 ·Investigational New Drugs ·Laura W. Goff, Nilofer S. Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka N. Vaishampayan, Howard S. Höchster, Roisín M. Connolly, Amy Weise, Patricia LoRusso, Safia N. Salaria, Wael El‐Rifai, Jordan Berlin	13
13	The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience 2018 ·Cancer Imaging ·Satya Das, (unknown), Laura W. Goff, Rachel K. Sobel, Jordan Berlin, George A. Fisher	20
14	An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC) 2016 ·Annals of Oncology ·Yung‐Jue Bang, Laura W. Goff, (unknown), Jing Yang, Gu Mi, Maria Karasarides, Martin Reck	0
15	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer 2016 ·Radiotherapy and Oncology ·Emily Chan, Lori R. Arlinghaus, Dana B. Cardin, Laura W. Goff, Jordan Berlin, Alexander A. Parikh, Richard G. Abramson, Thomas E. Yankeelov, Scott W. Hiebert, Nipun B. Merchant, Srividya Bhaskara, Anuradha Chakravarthy	59
16	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·Laura W. Goff, Roger B. Cohen, Jordan Berlin, Filippo de Braud, Andrej Lyshchik, Cristina Noberasco, Francesco Bertolini, M. Carpentieri, Corrado Gallo Stampino, Antonello Abbattista, (unknown), Hossein Borghaei	26
17	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Igor Puzanov, Colin R. Lindsay, Laura W. Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, (unknown), Andrew Stephens, (unknown), T.R. Jeffry Evans	78
18	Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers 2014 ·PLoS ONE ·Laura W. Goff, Nilay Thakkar, Liping Du, Emily Chan, Benjamin Tan, Dana B. Cardin, Howard L. McLeod, Jordan Berlin, Barbara A. Zehnbauer, (unknown), Joel Picus, Andrea Wang‐Gillam, Wooin Lee, A. Craig Lockhart	80
19	Advances in the management of biliary tract cancers. 2013 ·PubMed ·Kristen K. Ciombor, Laura W. Goff	20
20	Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy 2010 ·Digestive Diseases and Sciences ·(unknown), A. Bapsi Chakravarthy, Laura W. Goff, Wael El‐Rifai	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact